Skip to content

Annexon ANNX Net Change in Cash

Net Change in Cash at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$153.1M-125%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$576.58M+4,649%
Omeros logo
OmerosOMER
-$7.75M-1,001%
Vor Biopharma logo
Vor BiopharmaVOR
-$226.61M-610%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$13.25M-109%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$134.46M+2,610%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's net change in cash?
Annexon (ANNX) reported net change in cash of $13.16M in Q1 2026.
How has Annexon's net change in cash changed year-over-year?
Annexon's net change in cash decreased by 72.4% year-over-year, from $47.62M to $13.16M.
What is the long-term trend for Annexon's net change in cash?
Over 3 years (2021 to 2025), Annexon's net change in cash has grown at a -17.3% compound annual growth rate (CAGR), from -$198.88M to $112.55M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.